Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

U.S. drugmaker Merck said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

Merck & Co. cut its 2025 earnings outlook, partly to account for recently imposed tariffs that it projects will total $200 million. The projection comes in light of the tariffs implemented so ...

Merck expects $200 million in added tariff costs, primarily impacting gross margins. The company has invested $12 billion since 2017, with another $9 billion planned to expand U.S. manufacturing ...

Halozyme (HALO) filed a patent infringement lawsuit against Merck (MRK) in U.S. District Court in New Jersey. Halozyme believes the subcutaneous formulation of Merck’s cancer medicine ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US and China. The estimate doesn’t account for the possibility that ...

Caroline Litchfield; Chief Financial Officer, Executive Vice President; Merck & Co Inc Dean Li; Executive Vice President, President - Merck Research Laboratories; Merck & Co Inc Thank you for ...

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement may come as soon as Monday, the people said, asking not to be ...

Merck & Company (MRK) warns investors that it expects a $200 million hit from tariffs. Hasbro (HAS) stock is soaring after reporting a first quarter earnings beat. Comcast (CMCSA) stock sinks ...

You can reach Andrew on Signal at drewqjoseph.45. After months of discussion, Germany’s Merck KGaA said Monday it would buy SpringWorks Therapeutics for $47 a share in cash, a deal with an ...

Reacting to press speculation, Merck KGaA has acknowledged that talks to buy US biotech SpringWorks are now in the late stages and are revolving around an offer of around $47 per share.